- Patent Title: Tricyclic compounds for use in treatment of proliferative disorders
-
Application No.: US16494570Application Date: 2018-03-16
-
Publication No.: US11274098B2Publication Date: 2022-03-15
- Inventor: Andrew Morley , Rebecca Miller , Nicholas La Thangue
- Applicant: ARGONAUT THERAPEUTICS LIMITED
- Applicant Address: GB Oxford
- Assignee: ARGONAUT THERAPEUTICS LIMITED
- Current Assignee: ARGONAUT THERAPEUTICS LIMITED
- Current Assignee Address: GB Oxford
- Agency: Squire Patton Boggs (US) LLP
- Priority: GB1704325 20170317
- International Application: PCT/EP2018/056675 WO 20180316
- International Announcement: WO2018/167276 WO 20180920
- Main IPC: C07D471/04
- IPC: C07D471/04 ; C07D519/00
Abstract:
The present invention relates to compounds of Formula (I) as defined herein, and salts, hydrates and solvates thereof. The present invention also relates to pharmaceutical compositions comprising compounds of Formula (I), and to the use of compounds of Formula (I) in the treatment or prevention of PRMT5-mediated disorders, such as cancer.
Public/Granted literature
- US20200325132A1 TRICYCLIC COMPOUNDS FOR USE IN TREATMENT OF PROLIFERATIVE DISORDERS Public/Granted day:2020-10-15
Information query
